Merck & Co., Inc.
MRK evidence brief
What we can confirm
- BioSniper Score:
- 4.3 / 10
- Market Cap:
- $366.28B
- Next Catalyst:
- Patent_Expiry · May 29, 2033
What it means
What to watch
Prepared research question
What matters most for MRK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MRK
Merck & Co., Inc. (MRK) is a global pharmaceutical company preparing for the 2028 loss of exclusivity of its top-selling drug KEYTRUDA by investing in a broad pipeline of new therapies and business development, while reporting a net loss of $1,335.0M on revenue of $16,607.0M as of 2026-06-30 [sec].
Key risk: KEYTRUDA LOE in 2028
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 90 clinical trials · 3 catalysts for Merck & Co., Inc..
Merck & Co., Inc. (MRK) is a global pharmaceutical company preparing for the 2028 loss of exclusivity of its top-selling drug KEYTRUDA by investing in a broad pipeline of new therapies and business development, while reporting a net loss of $1,335.0M on revenue of $16,607.0M as of 2026-06-30 [sec].
- Cash & equivalents of $6,849.0M, total revenue of $16,607.0M, and a net loss of $1,335.0M as of 2026-06-30 [sec].
- Shareholders' equity of $41,933.0M and total debt of $53,906.0M as of 2026-06-30 [sec].
- Positive topline results from the pivotal Phase 2b/3 BRUNELLO trial for remigromig in diabetic macular edema announced September 24, 2026 [news].
- Merck is expanding its pipeline and newer drug portfolio to offset KEYTRUDA's 2028 loss of exclusivity [news].
- Upcoming patent expiries include SUVOREXANT (2033-05-29), RIOCIGUAT (2034-02-18), and BELZUTIFAN (2042-06-30) [catalyst].
What works
- Merck's pipeline includes a potentially first-in-class tri-specific Wnt pathway agonist, remigromig, which met its primary endpoint in a pivotal Phase 2b/3 trial [news].
- The company has a diversified pipeline with multiple Phase 2 and Phase 3 trials across oncology, inflammation, and other therapeutic areas [catalyst].
- Merck's Animal Health segment and new product launches are cited by the CEO as contributing to the company's transformation [news].
What to weigh
- Merck reported a net loss of $1,335.0M as of 2026-06-30, partly attributed to acquisition-driven losses [sec][news].
- The company faces the upcoming loss of exclusivity for KEYTRUDA in 2028, which represents a significant revenue defense challenge [news].
- Total debt of $53,906.0M exceeds shareholders' equity of $41,933.0M as of 2026-06-30, indicating a leveraged balance sheet [sec].
From the filings
Quoted directly from source documents.
Remigromig met primary endpoint in BRUNELLO trial
“announced positive topline results from its pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig”
News · September 28, 2026
Catalyst timeline
- 2033-05-29 · Patent_Expiry · SUVOREXANT — Patent expiry for SUVOREXANT (NDA204569); may open market to generic competition.
- 2034-02-18 · Patent_Expiry · RIOCIGUAT — Patent expiry for RIOCIGUAT (NDA204819); potential generic entry.
- 2042-06-30 · Patent_Expiry · BELZUTIFAN — Patent expiry for BELZUTIFAN (NDA215383); long-dated exclusivity end.
Risks & what to watch (3)›
Key risks
- KEYTRUDA LOE in 2028 — Loss of exclusivity for KEYTRUDA in 2028 threatens a major revenue stream; pipeline must compensate [news].
- Net loss and high debt — Net loss of $1,335.0M and total debt of $53,906.0M as of 2026-06-30 strain financial flexibility [sec].
- Pipeline execution risk — Reliance on pipeline readouts (e.g., remigromig) to offset LOE; any clinical failure could delay growth [news].
What to watch
- Clinical catalysts across oncology and broader pipeline over the next 12-18 months, which could drive a re-rating [news].
- Regulatory and clinical milestones for remigromig and other pipeline assets [news].
- Financial performance in upcoming quarters, especially net income trajectory and debt management [sec].
- Business development and partnership activity, such as the collaboration with Perspective Therapeutics [news].
Sources: Catalysts · News · Generated October 4, 2026 · How we verify sources →
Run Merck & Co., Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Merck & Co., Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 2.10 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
3 upcoming, next in ~2419d
0 buys · 17 sells (180d)
Catalysts
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 1.1%
- Days to cover
- 2.8
- Shares short
- 26,205,868
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MRK short interestGovernance
Frequently asked questions
What is the AI investment thesis for Merck & Co., Inc.?
Merck & Co., Inc. (MRK) is a global pharmaceutical company preparing for the 2028 loss of exclusivity of its top-selling drug KEYTRUDA by investing in a broad pipeline of new therapies and business development, while reporting a net loss of $1,335.0M on revenue of $16,607.0M as of 2026-06-30 [sec].
What is Merck & Co., Inc.'s next catalyst?
Merck & Co., Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA204569" — expected May 29, 2033.
Who is the CEO of Merck & Co., Inc.?
Mr. Robert M. Davis J.D. is the chief executive officer of Merck & Co., Inc. (MRK).
Where is Merck & Co., Inc. headquartered?
Merck & Co., Inc. (MRK) is headquartered in Rahway, NJ, United States.
What therapeutic areas does Merck & Co., Inc. focus on?
Merck & Co., Inc. develops therapies across Oncology, Rare Disease, Immunology, Ophthalmology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Dermatology, Hematology, Nephrology, Musculoskeletal, Gastroenterology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.